Citigroup
ANAC

Citigroup’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Citigroup’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-29,100
Closed -$1.55M – 7994
2016
Q1 		$1.55M Buy
29,100
+400
+1% +$29.5K ﹤0.01% 2814
2015
Q4 		$3.24M Buy
28,700
+15,700
+121% +$1.73M ﹤0.01% 2091
2015
Q3 		$1.53M Buy
+13,000
New +$1.7M ﹤0.01% 2695

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Citigroup's ANAC Position: Q2 2016 in Review

Citigroup sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 50,216 shares — an estimated $2.68M sold.

Citigroup first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $2.68M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Citigroup reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Citigroup sold 50,216 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.68M.
  • Citigroup first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Citigroup's ANACOR PHARMACEUTICALS INC COM position peaked at $2.68M in Q1 2016.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.